Intratumoral inflammation fosters angiogenesis and creates an immunosuppressive milieu. The self-amplifying loop of pro-angiogenic inflammation represents a serious obstacle for adaptive anti-cancer immune responses. We have previously demonstrated that restoration of tumour vessel function, so-called normalization, in the right inflammatory context “opens” tumours for therapy. We are developing new approaches which exploit the dynamic nature of tumour stroma to remodel rather than destroy vessels for longer lasting anti-tumour effects. Here, we report a new mechanism which restores differentiation of pericytes (mural cells of the microvasculature) and tumour vessel integrity. Targeting of LIGHT, a member of the TNFα cytokine family, into solid tumours increases anti-cancer immunity in an adjuvant setting. Prolonged survival is associated with vascular normalization, improved tumour perfusion and access of immune effector cells into tumour parenchyma. Vascular remodelling re-establishes pericyte-vessel alignment and, importantly, induces expression of contractile markers such as myocardin, caldesmon and calponin. Intriguingly, intratumoral LIGHT specifically re-programs tumour macrophages to secrete TGFβ which in turn enhances pericyte differentiation and normalizes the vascular bed in a locally restricted, RhoA-dependent manner. Thus, our findings highlight the plasticity and dynamic nature of tumour stroma and provide a specific approach to reverse angiogenesis.